COVID-19: China Healthcare Implications for Private Equity Investors Presentations July 14, 2020 Helen Chen Justin Wang Stephen Sunderland
Related Practice Private Equity We are seeking to drive practical insight from China’s experience to inform healthcare investment 01262022160120
Executive Insights Biotech and Pharmaceuticals Drug Manufacturing Trends Impacting Biopharma Stakeholders in the Post-COVID-19 Era May 23, 2024
Case Study Life Sciences & Pharma Cost and Reimbursement Assessment for a Biopharmaceutical Company May 7, 2024 A large biopharmaceutical company developing chimeric antigen receptor T-cell (CAR-T) therapies
Published Articles Marketing & Sales Understanding the ‘Cookie Apocalypse’ and Its Impact on Online Advertising February 23, 2024
Executive Insights Life Sciences & Pharma Optimizing Pharmaceutical Portfolios Through M&A January 16, 2024
Article Life Sciences & Pharma Hospital Priorities in China in 2023: Strategic Implications for Pharma Companies December 7, 2023